Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of April 2022, with the report issued on April 19, 2022. The filing announces a significant regulatory milestone for GSK's pharmaceutical pipeline regarding the treatment of anaemia of chronic kidney disease (CKD).
Key Financial Metrics
The filing text does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on a regulatory development rather than financial performance.
Material Changes and Regulatory Milestones
- FDA Acceptance: The US Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for daprodustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI).
- Indication: The application is for the potential treatment of patients with anaemia of chronic kidney disease (CKD), covering both non-dialysis and dialysis patients.
- Timeline: The FDA has assigned a Prescription Drug User Fee Act (PDUFA) action date of February 1, 2023.
- Global Progress: This acceptance follows the approval of daprodustat (marketed as Duvroq) in Japan and the validation of the marketing authorisation application (MAA) by the European Medicines Agency (EMA) in March 2022.
Clinical Data and Management Commentary
The NDA is supported by the ASCEND phase III clinical trial programme, which enrolled over 8,000 patients treated for up to 4.26 years. Key findings include:
- Efficacy: Five pivotal trials met their primary efficacy and safety endpoints. Daprodustat improved and/or maintained haemoglobin (Hb) within the target level (10-11.5 g/dL) compared to the standard of care (erythropoietin stimulating agents).
- Safety: In the intention-to-treat populations for both non-dialysis (ASCEND-ND) and dialysis (ASCEND-D) settings, daprodustat demonstrated non-inferiority regarding major adverse cardiovascular events (MACE) compared to the control group.
- Publication: Results from the key cardiovascular outcomes trials were published in the New England Journal of Medicine in November 2021.
Management highlights that daprodustat is based on Nobel Prize-winning science regarding cellular oxygen sensing and offers a convenient oral treatment option.
Risks and Contingencies
The filing includes a cautionary statement regarding forward-looking statements. GSK notes that actual results may differ materially from projections due to risks and uncertainties, including those described in the 2021 Annual Report on Form 20-F and potential impacts from the COVID-19 pandemic.
Investor Verification Checklist
- Verify the PDUFA action date of February 1, 2023, for the US FDA decision on daprodustat.
- Confirm the status of the European Medicines Agency (EMA) review following the March 2022 validation.
- Review the full ASCEND phase III trial data published in the New England Journal of Medicine to assess long-term safety profiles.
- Monitor upcoming regulatory filings anticipated throughout 2022 for additional markets.
- Check for any updates on the commercial launch strategy for daprodustat in the US pending FDA approval.